• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

MacroGenics

edit

MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company’s Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.

Recent Milestones

edit

• 
  MacroGenics — MacroGenics banks $20M in potential $1.1B cancer-drugs deal with Servier (9/20/12)
  Posted 9/20/12 at 7:24pm via fiercebiotech.com
• 
  MacroGenics acquired Raven Biotechnologies. (7/17/08)
  Posted 9/14/09 at 6:45am via biospace.com
• 
  MacroGenics received $45M in Series C funding. (5/17/06)
  Posted 4/19/10 at 11:38pm via macrogenics.com
• 
  MacroGenics added Scott Koenig as President and Chief Executive Officer.
  Posted 9/14/09 at 6:43am
• 
  MacroGenics added Jeffrey V. Ravetch as Co-founder .
  Posted 9/14/09 at 6:43am
• 
  MacroGenics added James Karrels as Vice President, Chief Financial Officer.
  Posted 1/12/13 at 3:16am
• 
  MacroGenics added Ezio Bonvini as Senior Vice President, Research.
  Posted 1/12/13 at 3:16am

Videos

Screenshots

edit

Above: MacroGenics
Uploaded: 4/20/10

Sources

1. MacroGenics, Inc. (JOBS) Acquires Raven Biotechnologies, Inc. (biospace.com) [edit]
2. MacroGenics Raises $45M in Series C Financing - Company to Advance Monoclonal Antibody Clinical Programs (macrogenics.com) [edit]
MacroGenics banks $20M in potential $1.1B cancer-drugs deal with Servier (fiercebiotech.com) [edit]